Population Pharmacokinetics study of Imatinib

Population Pharmacokinetics study of Imatinib in CML patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014050612206N1

Enrollment

220

Registered

2014-05-15

Start date

2014-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myeloid leukaemia (CML). Chronic myeloid leukaemia [CML], BCR/ABL-positive

Interventions

Observational Study.

Observational Study

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with CML in chronic phase who take Imatinib from diagnosis and have no other disease. Exclusion Criteria: taking Interfron or Hydroxyurea in past or during the study; taking drugs that induce or inhibit liver microsomal enzymes and patients in accelerated or blastic phases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Trough plasma concentration. Timepoint: Before taking the dose. Method of measurement: HPLC.	—

Secondary

Measure	Time frame
Hematological response. Timepoint: every 3 months. Method of measurement: CBC Check.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Mohjeri

Kerman University of Medical Sciences

ehsandaru@gmail.com+98 913 199 7114

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026